Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Oppenheimer Reaffirms Their Buy Rating on Marinus (MRNS) - Markets
01:54am, Wednesday, 01'st Jul 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on Marinus (MRNS – Research Report) yesterday and set a price target
RBC Capital Remains a Hold on Iterum Therapeutics (ITRM) - Markets
11:21am, Tuesday, 30'th Jun 2020
RBC Capital analyst Gregory Renza maintained a Hold rating on Iterum Therapeutics (ITRM – Research Report) yesterday and set a
Needham Thinks Intercept Pharma's Stock is Going to Recover - Markets
10:46am, Tuesday, 30'th Jun 2020
In a report released today, Alan Carr from Needham assigned a Buy rating to Intercept Pharma (ICPT – Research Report),
Analysts Offer Insights on Healthcare Companies: Cryolife (NYSE: CRY) and Seattle Genetics (NASDAQ: SGEN) - Markets
09:22am, Tuesday, 30'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cryolife (CRY
Dow Surges 2.3% as Boeing Begins Testing the 737 Max
12:00am, Tuesday, 30'th Jun 2020
Stocks Analysis by Zacks Investment Research covering: Boeing Co, Ciena Corp, Lennar Corporation, Verizon Communications Inc. Read Zacks Investment Research's latest article on Investing.com
Biotech Could Burst Higher, Says Signal
07:50pm, Monday, 29'th Jun 2020
ACADIA stock is flashing a bull signal that could launch it back toward its all-time highs
Analyst Explains Why They Downgraded Their Rating on Intercept Pharma (ICPT) - Markets
01:29pm, Monday, 29'th Jun 2020
In a report released today, Jay Olson from Oppenheimer downgraded Intercept Pharma (ICPT – Research Report) to Hold, with a
Biotech Could Burst Higher, Says Signal - Schaeffer's Investment Research
07:50am, Monday, 29'th Jun 2020
Several layers of support are in place for ACADIA Pharmaceuticals Inc (ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Legal & General Group Plc
06:08am, Friday, 26'th Jun 2020
Legal & General Group Plc grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 8.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 78,
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
12:00am, Thursday, 25'th Jun 2020
The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
ACADIA...
Needham Believes Rhythm Pharmaceuticals (NASDAQ: RYTM) Still Has Room to Grow - Markets
06:36pm, Wednesday, 24'th Jun 2020
Needham analyst Alan Carr assigned a Buy rating to Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price
2 Biotech Stocks With Major Incoming Catalysts | The Motley Fool
10:49am, Wednesday, 24'th Jun 2020
While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Hosts 2020 Annual Meeting of Stockholders (Transcript)
12:52pm, Tuesday, 23'rd Jun 2020
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 2020 Annual Meeting of Stockholders June 23, 2020 10:00 AM ET Company Participants Steve Biggar - Chairman of the Boar
Ayala Pharmaceuticals (AYLA) Receives a Buy from Oppenheimer - Markets
03:14am, Tuesday, 23'rd Jun 2020
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report),
